Locipil Tablet contains a combination of Ethinyl Estradiol (0.02 mg) and Desogestrel (0.15 mg), which are synthetic hormones used primarily for oral contraception. Ethinyl Estradiol is a synthetic estrogen, while Desogestrel is a progestin, both working synergistically to prevent ovulation, alter the cervical mucus to inhibit sperm penetration, and modify the endometrial lining to prevent implantation. Locipil is indicated for the prevention of pregnancy in women seeking reliable contraceptive methods. It is administered orally, typically once daily, and should be taken at the same time each day to maximize efficacy. The low-dose formulation aims to minimize hormonal side effects while maintaining contraceptive effectiveness. Contraindications include a history of thromboembolic disorders, hormone-sensitive malignancies, undiagnosed vaginal bleeding, and known hypersensitivity to any component of the tablet. Common adverse effects may include nausea, headache, breast tenderness, and breakthrough bleeding, which usually subside after the initial months of use. Patients should be advised to inform their healthcare provider of any history of cardiovascular disease, liver dysfunction, or smoking habits, as these factors may increase the risk of serious complications. Locipil Tablet does not protect against sexually transmitted infections and should be used as directed under medical supervision.